Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ranica – page 210

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
2 668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 668 trials in Ranica

Open in trial search

Study of Loncastuximab Tesirine and Rituximab for Untreated Unfit or Frail Patients with Diffuse Large B-cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Rituximab
  • Sponsor:ADC Therapeutics SA
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:GlaxoSmithKline Biologicals

Study on Botensilimab Alone and with Balstilimab or Drug Combination for Patients with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

B-cell lymphoma+1

Not recruiting

Study on UCART20x22 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Using a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Cellectis

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study of Zilovertamab Vedotin with Drug Combination for Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hansa Biopharma AB

Colon cancer+3

Not recruiting

Study on High-Dose Vitamin C with Ipilimumab and Nivolumab for Patients with Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

HIV infection

Not recruiting

Study Comparing Bictegravir and Lenacapavir to Current Treatment in Patients with HIV-1 on Complex Regimens

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Colitis ulcerative+2

Not recruiting

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Dementia+1

Not recruiting

Study on Donanemab Dosing for Adults with Early Alzheimer's Disease

Registered drug
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Donanemab
  • Sponsor:Eli Lilly & Co.

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.